WaveMan
WaveMan · Company
MLYS · Mineralys Therapeutics, Inc.
> Search tickers & screens ⌘K
LIVE
← All companies

MLYS Mineralys Therapeutics (MLYS) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Pharmaceutical preparations · CIK 0001933414
Quote by TradingView
Form 144 · 12
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
125
13F, latest reported quarter
Conversions, 180 days
22
Codes C/M, not in net · $2.2M priced

What the filings say about MLYS

Insiders, 180 days
-$12.5M net sold
5 sellers · 17% of sales under a 10b5-1 plan
Planned sales (Form 144), 90 days
$6.2M
12 notices

Mineralys Therapeutics insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

Over the last 180 days, Mineralys Therapeutics, Inc. insiders sold a net $12.5M of stock across 145 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-28.

Insider
Filed
Shares
Value
Since filing
Congleton Jon
Chief Executive Officer
SELL
2026-10-02 SECtraded 2026-09-30
75,000
$1.9M
-11.8%
Context
  • 32 earlier Form 4 trades (code P or S) here by this insider (4 buys, 28 sales), the last on Jul 13, 2026.
  • -43.1% median (+6.6% mean) 90-day return after 4 previous buys.
  • The trade is 14.2% of the 528,621 shares held after it.
  • 3 other insiders sold within 30 days.
  • 125 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Executive Officer Congleton Jon sold about $1.9M of MLYS under a 10b5-1 plan on Sep 30, 2026; 3 other insiders sold within 30 days and 125 funds added in the latest 13F quarter.
Slingsby Brian Taylor
Director
SELL
2026-09-24 SECtraded 2026-09-22
104,320
$3.0M
-20.5%
Context
  • 3 earlier Form 4 trades (code P or S) here by this insider (2 buys, 1 sale), the last on Mar 13, 2025.
  • +2.5% median (+2.5% mean) 90-day return after 2 previous buys.
  • The trade is 1.3% of the 7,805,718 shares held after it.
  • 3 other insiders sold within 30 days.
  • 125 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Slingsby Brian Taylor sold about $3.0M of MLYS on Sep 22, 2026; 3 other insiders sold within 30 days and 125 funds added in the latest 13F quarter.
Warren Eric
Chief Commercial Officer
SELL
2026-09-22 SECtraded 2026-09-21
7,438
$209.1K
-23.5%
Context
  • 3 earlier Form 4 trades (code P or S) here by this insider (3 sales), the last on Aug 21, 2026.
  • The trade is 19.4% of the 38,400 shares held after it.
  • 3 other insiders sold within 30 days.
  • 125 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Commercial Officer Warren Eric sold about $209.1K of MLYS under a 10b5-1 plan on Sep 21, 2026; 3 other insiders sold within 30 days and 125 funds added in the latest 13F quarter.
Karydas Daphne
Director
SELL
2026-09-17 SECtraded 2026-09-15
3,000
$85.7K
-26.6%
Context
  • 4 earlier Form 4 trades (code P or S) here by this insider (4 sales), the last on Jun 17, 2026.
  • The trade is 48.4% of the 6,200 shares held after it.
  • 3 other insiders sold within 30 days.
  • 125 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Karydas Daphne sold about $85.7K of MLYS under a 10b5-1 plan on Sep 15, 2026; 3 other insiders sold within 30 days and 125 funds added in the latest 13F quarter.
Warren Eric
Chief Commercial Officer
SELL
2026-08-25 SECtraded 2026-08-21
7,437
$193.2K
-20.6%
Context
  • 2 earlier Form 4 trades (code P or S) here by this insider (2 sales), the last on Jul 21, 2026.
  • The trade is 19.4% of the 38,400 shares held after it.
  • 2 other insiders sold within 30 days.
  • 125 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Commercial Officer Warren Eric sold about $193.2K of MLYS under a 10b5-1 plan on Aug 21, 2026; 2 other insiders sold within 30 days and 125 funds added in the latest 13F quarter.
145 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 140 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
net -$12.5M over 180 days
-$5.5M over 90 days
below 86% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
125 funds bought in last quarter
more than 77% of Pharma & Biotech
Revenue
no revenue reported in any filing
Margin
no margin: no revenue reported
Buybacks
no share repurchases reported
Short interest
11.7% of the float short (float per yahoo 2026-10-26) · 5.2 days to cover · settled 2026-09-30
more than 67% of Pharma & Biotech
What changed in the last 30 days
Oct 13Officer Rodman David Malcom filed to sell $78.1K by Oct 13 (Form 144)
Why it matters
A Form 144 is a notice of intent to sell; the sale may not happen, and it says nothing about the price.
Oct 2Chief Executive Officer Congleton Jon sold $1.9M under a 10b5-1 plan (Sep 30)
Why it matters
A 10b5-1 plan schedules trades months ahead, so this says little about what the insider thinks today.
Sep 30Officer Congleton Jon filed to sell $1.9M by Sep 30 (Form 144)
Why it matters
A Form 144 is a notice of intent to sell; the sale may not happen, and it says nothing about the price.

Watch MLYS

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-49.6%12M
-50%-28%-6%+16%2025-102025-122026-022026-042026-062026-082026-10 2025-11-20 · Catalys Pacific Fund, LP sold $43.4M2026-03-27 · Shah Rajeev M. bought $7.4M2025-11-11 · Congleton Jon sold $5.1M2026-01-05 · Rodman David Malcom sold $4.8M2026-09-22 · Slingsby Brian Taylor sold $3.0M2026-06-26 · Warren Eric sold $2.7M2026-01-02 · Rodman David Malcom sold $2.5M2026-09-30 · Congleton Jon sold $1.9M2026-01-05 · Rodman David Malcom sold $1.9M2025-11-11 · Levy Adam Scott sold $1.8M2025-11-11 · Congleton Jon sold $1.5M2025-11-11 · Levy Adam Scott sold $1.5M2026-06-30 · Congleton Jon sold $1.5M2026-03-31 · Congleton Jon sold $1.5M2026-03-30 · Shah Rajeev M. bought $1.4M2025-11-11 · Congleton Jon sold $1.3M2025-11-13 · Gold Alexander M sold $592.5K2025-11-11 · Levy Adam Scott sold $539.5K2025-11-11 · Congleton Jon sold $533.2K2026-03-31 · Congleton Jon sold $493.8K2025-11-11 · Levy Adam Scott sold $472.9K2025-11-13 · Karydas Daphne sold $463.4K2026-06-30 · Congleton Jon sold $455.9K2025-11-11 · Gold Alexander M sold $424.3K2026-04-13 · Congleton Jon sold $422.0K2026-05-13 · Rodman David Malcom sold $401.7K2026-07-13 · Rodman David Malcom sold $387.7K2025-11-11 · Levy Adam Scott sold $382.0K2025-11-11 · Congleton Jon sold $375.0K2026-04-13 · Rodman David Malcom sold $373.1K2026-01-14 · Rodman David Malcom sold $370.7K2025-11-11 · Levy Adam Scott sold $359.3K2026-01-12 · Levy Adam Scott sold $345.8K2026-01-12 · Congleton Jon sold $293.7K2026-07-13 · Congleton Jon sold $291.4K2026-03-13 · Rodman David Malcom sold $277.9K2026-01-13 · Rodman David Malcom sold $252.5K2026-01-12 · Congleton Jon sold $235.9K2026-06-15 · Rodman David Malcom sold $235.5K2025-11-11 · Gold Alexander M sold $235.4K2025-11-12 · Gold Alexander M sold $232.5K2025-11-13 · Karydas Daphne sold $226.5K2026-10-13 · Rodman David Malcom filed to sell $78.1K2026-09-30 · Congleton Jon filed to sell $1.9M2026-09-22 · CATALYS PACIFIC FUND LP filed to sell $3.0M2026-09-21 · Warren Eric filed to sell $209.1K2026-09-17 · Rodman David Malcom filed to sell $11.7K2026-09-15 · Karydas Daphne filed to sell $85.7K2026-09-14 · Rodman David Malcom filed to sell $216.9K2026-09-09 · Rodman David Malcom filed to sell $67.0K2026-08-21 · Warren Eric filed to sell $193.2K2026-08-17 · Rodman David Malcom filed to sell $10.6K2026-08-13 · Rodman David Malcom filed to sell $372.2K2026-08-10 · Rodman David Malcom filed to sell $58.8K2026-07-21 · Warren Eric filed to sell $199.9K2026-07-17 · Rodman David Malcom filed to sell $11.0K2026-07-15 · Rodman David Malcom filed to sell $169.0K2026-07-13 · Congleton Jon filed to sell $291.4K2026-07-13 · Rodman David Malcom filed to sell $387.7K2026-07-09 · Rodman David Malcom filed to sell $65.8K2026-06-30 · Congleton Jon filed to sell $2.0M2026-06-29 · Warren Eric filed to sell $2.7M
Insider buyInsider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns MLYS: institutional holders (13F)

13F holdings, latest reported quarter
Catalys Pacific, LLC
7,903,838 sh
$213.2M
RA CAPITAL MANAGEMENT, L.P.
7,692,750 sh
$207.6M
BlackRock, Inc.
5,887,038 sh
$158.8M
SAMSARA BIOCAPITAL, LLC
5,871,018 sh
$158.4M
FMR LLC
4,511,689 sh
$121.7M

Congress trades in MLYS

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

MLYS planned insider sales (Form 144)

Notice of intent to sell, filed before any sale
Rodman David Malcom
Filed 2026-10-13
$78.1K
Congleton Jon
Filed 2026-09-30
$1.9M
CATALYS PACIFIC FUND LP
Filed 2026-09-22
$3.0M
Warren Eric
Filed 2026-09-21
$209.1K
Rodman David Malcom
Filed 2026-09-17
$11.7K

MLYS mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
ALPS Medical Breakthroughs ETF
$2.6M position · as of 2026-05-31
1.6%
Franklin Biotechnology Discovery Fund
$13.6M position · as of 2026-07-31
1.2%
PGIM Jennison Health Sciences Fund
$14.5M position · as of 2026-05-29
1.0%
Virtus Biotech Clinical Trials Etf
$335.8K position · as of 2026-07-31
0.7%
State Street(R) SPDR(R) S&P(R) Biotech ETF
$76.1M position · as of 2026-06-30
0.7%
PROFUND VP BIOTECHNOLOGY
$336.5K position · as of 2026-06-30
0.7%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Clinical pipeline
6 registered trials, 1 still running (ClinicalTrials.gov). A status change is dated here weeks before the press release.
4
Phase 2
0 active
2
Phase 3
1 active
Matched by sponsor name. Trials run under a subsidiary's own name are not included.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders have filed to sell, before selling.
The record shows a net $12.5M sold by insiders over 180 days, 125 funds added last quarter, $6.2M in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWST

MLYS financials

Ratios from the company's XBRL filings, latest filings
Revenue, TTM
n/a
fewer than four consecutive quarters of revenue filed
Net margin, TTM
n/a
needs four consecutive quarters of both revenue and net income
Free cash flow, TTM
-$138.8M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Debt to equity
0.00x
long-term debt only, 2026-06-30; equity 2026-06-30
Cash flow to debt
-1,387.87x
TTM operating cash flow over long-term debt only, 2026-06-30
Return on equity
-80.9%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets
-69.7%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on invested capital
n/a
tax provision or pre-tax income not filed for the four quarters
Return on capital employed
-77.1%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Enterprise value
$1.7B
market value at close 2026-10-26 on 2026-08-03 shares, plus long-term debt only, 2026-06-30, minus cash 2026-06-30
FCF yield
-7.6%
TTM free cash flow over market value at close 2026-10-26
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-122023-122022-12
Operating income-$170.6M-$192.4M-$84.7M-$31.5M
Net income-$154.7M-$177.8M-$71.9M-$29.8M
EPS (diluted)-2.29-3.66-1.99-5.77
Operating cash flow-$142.4M-$166.3M-$81.2M-$29.2M
Cash$172.9M$114.1M$49.3M$87.7M
SEC XBRL, fiscal years, as known on 2026-10-28

MLYS Stock Sonar score 5/7 axes

Find similar shapesCompare

MLYS ranks highest on institutional and government (77th percentile) and financial health (44th), and lowest on insider conviction (7th), among Pharma & Biotech peers.

ProfitHealthInsidersInstitutionsRisk
Profitability
35
Inputs
  • Return on equity-80.9% · 38 pct, sector of 545
  • Return on assets-69.7% · 34 pct, sector of 691
  • Return on invested capitaltax provision or pre-tax income not filed for the four quarters
  • Return on capital employed-77.1% · 34 pct, sector of 576
Financial health
44
Inputs
  • Debt to equity0.00x · 87 pct, sector of 352
  • Cash flow to debt-1387.87x · 1 pct, sector of 371
Insider conviction
7
Inputs
  • Net Form 4 buying (codes P and S), 180d-$10.1M · 14 pct, sector of 428
  • Insider buyers, 180d0 · 0 pct, sector of 437
Institutional and government
77
Inputs
  • Funds adding, latest quarter125 · 77 pct, sector of 698
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quartersno lobbying filings in the last four quarters
Risk and compliance
34
Inputs
  • Short interest, % of float+11.7% · 34 pct, sector of 813
  • Recalls per $1B revenue, 3yrevenue under $50M or not filed, so a count cannot be scaled to size
  • EPA cases per $1B revenue, 5yrevenue under $50M or not filed, so a count cannot be scaled to size
  • New text in Risk Factors, latest 10-Kneeds two 10-Ks with a Risk Factors section (not 20-F filers or stubs)
2 not measured: Growth, US patents
  • Growth needs 1 of 2 inputs, 0 present: no backlog line filed, or no year-earlier backlog; no revenue for this year and the year before
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

5 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

MLYS filings, in plain words

Are Mineralys Therapeutics insiders buying or selling MLYS?

In the 180 days to 2026-10-28, Mineralys Therapeutics insiders were net sellers, a net $12.5M across purchases and sales reported on Form 4, by 5 sellers.

Are there planned insider sales of MLYS?

Yes. 12 Form 144 notices of planned insider sales were filed in the 90 days to 2026-10-28, covering $6.2M of stock; the latest, by Rodman David Malcom, was filed 2026-10-13.

Read the full summary

In the 180 days to 2026-10-28, Mineralys Therapeutics insiders were net sellers of MLYS, a net $12.5M across purchases and sales reported on Form 4 by 5 sellers. 17% of the 24 insider sales were made under a Rule 10b5-1 plan; the rest were not flagged as planned. Insiders filed 12 Form 144 notices of intent to sell in the 90 days to 2026-10-28, covering $6.2M of stock. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies